Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J closes Pfizer deal

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson announces Dec. 20 the closing of its previously announced acquisition of Pfizer Consumer Healthcare for $16.6 billion in cash. "The completion of the Pfizer Consumer Healthcare acquisition builds upon our broad base in health products and reflects our longstanding strategy of leadership within attractive health care markets," J&J Chairman and CEO William C. Johnson says. Brands included in the transaction include Listerine, Nicorette and Sudafed. The Federal Trade Commission cleared the transaction Dec. 12 (1"The Tan Sheet" Dec. 18, 2006, p. 9)...

You may also be interested in...

New Products In Brief

Listerine anticavity: New Listerine Tooth Defense contains fluoride to "strengthen tooth enamel and protect against caries," McNeil announces. The mouthwash helps decrease caries at the root surface and enamel crown, inhibits the demineralization of enamel and enhances mineralization, McNeil claims. Available in Mint-Shield flavor, the product will carry suggested retail prices of $3.29 to $5.89. Although Tooth Defense kills germs that cause oral malodor, it is "not intended to help prevent or reduce plaque and gingivitis," the company notes. Johnson & Johnson picked up the brand after it closed its Pfizer Consumer Healthcare acquisition in December for $16.6 bil. in cash (1"The Tan Sheet" Jan. 1, 2007, In Brief). J&J divested its ACT fluoride mouth rinse to Chattem Jan. 2 in conjunction with the Pfizer acquisition (2"The Tan Sheet" Feb. 19, 2007, p. 10)...

Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J

Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings

J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off

Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts